IL-8 level based method of predicting the outcome of colon cancer treatment
The present invention concerns the use of interleukin-8 (IL-8) as a biomarker for predicting the outcome of the treatment with aflibercept, or ziv-aflibercept of a patient suspected to suffer from a cancer.
1. A method for treating a patient with colon cancer, colorectal cancer or a rectal cancer with 1 mg/kg-10 mg/kg aflibercept, or ziv-aflibercept, 200 mg/m 2 -600 mg/m 2 folinic acid, 2000 mg/m 2 -4000 mg/m 2 5-fluorouracil (5-FU) and either 85 mg/m 2 oxaliplatin or 100 mg/m 2 -300 mg/m 2 irinotecan to the patient, wherein a biological sample obtained from the patient has an interleukin-8 (IL-8) level that is lower than a reference level of IL-8.
2. The method according to claim 1 , wherein the reference level of IL-8 is between 10 and 30 pg/ml.
3. The method according to claim 1 , wherein the reference level of IL-8 is 19 pg/ml.
4. The method according to claim 1 , wherein the biological sample is selected from the group consisting of blood, serum, and plasma.
5. The method according to claim 1 , wherein the colorectal cancer is a metastatic colorectal cancer.
6. The method according to claim 1 , wherein the IL-8 level is a circulating level.
7. The method according to claim 1 , wherein said patient has previously been treated with oxaliplatin or bevacizumab.
8. The method according to claim 1 , wherein folinic acid is administered at a dosage of about 400 mg/m 2 , 5-FU is administered at a dosage of about 2800 mg/m 2 , irinotecan is administered at a dosage of about 180 mg/m 2 , and aflibercept at a dosage of about 4 mg/kg.
9. The method according to claim 8 , wherein oxaliplatin, folinic acid, 5-FU, irinotecan, and aflibercept are administered every two weeks.
10. The method according to claim 8 , wherein oxaliplatin, folinic acid, 5-FU, irinotecan and aflibercept are administered intravenously every two weeks for a period of between 9 and 18 weeks.